The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin - PubMed (original) (raw)
Comparative Study
. 2000 Aug 4;275(31):23899-903.
doi: 10.1074/jbc.C000276200.
Affiliations
- PMID: 10843985
- DOI: 10.1074/jbc.C000276200
Free article
Comparative Study
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al. J Biol Chem. 2000.
Free article
Abstract
Mutations in breast cancer tumor susceptibility genes, BRCA1 and BRCA2, predispose women to early onset breast cancer and other malignancies. The Brca genes are involved in multiple cellular processes in response to DNA damage including checkpoint activation, gene transcription, and DNA repair. Biochemical interaction with the recombinational repair protein Rad51 (Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., and Livingston, D. M. (1997) Cell 90, 425-435), as well as genetic evidence (Moynahan, M. E., Chiu, J. W., Koller, B. H., and Jasin, M. (1999) Mol. Cell 4, 511-518 and Snouwaert, J. N., Gowen, L. C., Latour, A. M., Mohn, A. R., Xiao, A., DiBiase, L., and Koller, B. H. (1999) Oncogene 18, 7900-7907), demonstrates that Brca1 is involved in recombinational repair of DNA double strand breaks. Using isogenic Brca1(+/+) and brca1(-/-) mouse embryonic stem (ES) cell lines, we investigated the role of Brca1 in the cellular response to two different categories of DNA damage: x-ray induced damage and cross-linking damage caused by the chemotherapeutic agent, cisplatinum. Immunoflourescence studies with normal and brca1(-/-) mutant mouse ES cell lines indicate that Brca1 promotes assembly of subnuclear Rad51 foci following both types of DNA damage. These foci are likely to be oligomeric complexes of Rad51 engaged in repair of DNA lesions or in processes that allow cells to tolerate such lesions during DNA replication. Clonogenic assays show that brca1(-/-) mutants are 5-fold more sensitive to cisplatinum compared with wild-type cells. Our studies suggest that Brca1 contributes to damage repair and/or tolerance by promoting assembly of Rad51. This function appears to be shared with Brca2.
Similar articles
- BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. Yuan SS, et al. Cancer Res. 1999 Aug 1;59(15):3547-51. Cancer Res. 1999. PMID: 10446958 - BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway.
Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. Chen JJ, et al. Cancer Res. 1999 Apr 1;59(7 Suppl):1752s-1756s. Cancer Res. 1999. PMID: 10197592 - The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.
Zhou C, Huang P, Liu J. Zhou C, et al. Biochem Biophys Res Commun. 2005 Oct 28;336(3):952-60. doi: 10.1016/j.bbrc.2005.08.197. Biochem Biophys Res Commun. 2005. PMID: 16165098 - Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN, Kachnic LA. Powell SN, et al. Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267. Anticancer Agents Med Chem. 2008. PMID: 18473729 Review. - Cancer susceptibility and the functions of BRCA1 and BRCA2.
Venkitaraman AR. Venkitaraman AR. Cell. 2002 Jan 25;108(2):171-82. doi: 10.1016/s0092-8674(02)00615-3. Cell. 2002. PMID: 11832208 Review.
Cited by
- Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches.
Guffanti F, Mengoli I, Damia G. Guffanti F, et al. Front Oncol. 2024 Aug 16;14:1405361. doi: 10.3389/fonc.2024.1405361. eCollection 2024. Front Oncol. 2024. PMID: 39220639 Free PMC article. Review. - Targeting DNA Damage Response Deficiency in Thoracic Cancers.
Bzura A, Spicer JB, Dulloo S, Yap TA, Fennell DA. Bzura A, et al. Drugs. 2024 Sep;84(9):1025-1033. doi: 10.1007/s40265-024-02066-9. Epub 2024 Jul 13. Drugs. 2024. PMID: 39001941 Review. - Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators.
Jadav R, Weiland F, Noordermeer SM, Carroll T, Gao Y, Wang J, Zhou H, Lamoliatte F, Toth R, Macartney T, Brown F, Hastie CJ, Alabert C, van Attikum H, Zenke F, Masson JY, Rouse J. Jadav R, et al. Mol Cell Proteomics. 2024 Aug;23(8):100802. doi: 10.1016/j.mcpro.2024.100802. Epub 2024 Jun 15. Mol Cell Proteomics. 2024. PMID: 38880245 Free PMC article. - A deep-learning-based genomic status estimating framework for homologous recombination deficiency detection from low-pass whole genome sequencing.
Liu Y, Bi X, Leng Y, Chen D, Wang J, Ma Y, Zhang MZ, Han BW, Li Y. Liu Y, et al. Heliyon. 2024 Feb 9;10(4):e26121. doi: 10.1016/j.heliyon.2024.e26121. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38404843 Free PMC article. - Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer.
Luo Y, Pan R, Rao H, Chen X, Yang H. Luo Y, et al. Int J Gen Med. 2024 Jan 11;17:75-84. doi: 10.2147/IJGM.S445660. eCollection 2024. Int J Gen Med. 2024. PMID: 38226182 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous